FIELD: medicine, narcology.
SUBSTANCE: invention involves using immunogenic monoclonal antibodies raised to opiates as an agent used in prophylaxis and treatment and treatment of opiomania. Invention provides expanding assortment of pathogenetic agents used in treatment and prophylaxis of opiomania and enhancing effectiveness in treatment. Invention can be used in prophylaxis and treatment of opiomania.
EFFECT: enhanced and valuable properties of agent.
2 cl, 1 tbl, 6 ex
Title | Year | Author | Number |
---|---|---|---|
IMMUNOGEN FOR TREATING AND PREVENTING OPIATE ADDICTION | 2013 |
|
RU2548802C1 |
PREPARATION FOR TREATING OPIUM NARCOMANIA | 2001 |
|
RU2201761C1 |
MONOCLONAL ANTI-IDIOTYPIC ANTIBODY AI-K11B, HAVING ANTIGENIC PROPERTIES OF MORPHINE | 2020 |
|
RU2745374C1 |
MONOCLONAL ANTIBODY 6G1 TO MORPHINE DERIVATIVES | 2018 |
|
RU2703494C1 |
SYNTHETIC IMMUNOGEN FOR PROTECTION AND TREATMENT OF PSYCHOACTIVE SUBSTANCES ADDICTION | 2016 |
|
RU2643329C1 |
SYNTHETIC IMMUNOGEN FOR THERAPY AND PROPHYLAXIS OF ADDICTION WITH NARCOTIC AND PSYCHOACTIVE SUBSTANCES | 2003 |
|
RU2236257C1 |
SYNTHETIC IMMUNOGEN FOR PROTECTION AND TREATMENT OF PSYCHOACTIVE SUBSTANCES ADDICTION | 2016 |
|
RU2635517C1 |
SYNTHETIC IMMUNOGEN FOR PROTECTION AGAINST TOXIC ACTION OF NARCOTIC AND PSYCHOACTIVE SUBSTANCES | 2012 |
|
RU2526807C2 |
AGENT FOR ABSTINENT SYNDROME ARRESTING AT OPIOMANIA | 1993 |
|
RU2083204C1 |
MONOCLONAL ANTIBODY 3K11 TO MORPHINE DERIVATIVES | 2018 |
|
RU2702002C1 |
Authors
Dates
2005-11-20—Published
2002-10-22—Filed